检索结果-南通市图书馆

World Journal of Gastroenterology 2006年第28期12卷 4546-4548页

作者： Hidenori Toyoda takashi kumada Olivier Bregerie Christian Brechot Chantal Desdouets Department of Gastroenterology Ogaki Municipal HospitalOgakiJapan Inserm U370-Pasteur Institute CHU NeckerParisFrance

AIM： TO analyze the percentages of hepatocytes with increased nuclear DNA content, i.e., tetraploid （4n） and octoploid （Sn） nuclei, and then compared mononuclear and binuclear hepatocyte populations： METHODS： The percentages of mononuclear diploid （2n）, 4n, and 8n hepatocytes and those of binuclear 2 × 2n, 2 × 4n, and 2 × 8n hepatocytes were determined with a method that can simultaneously measure hepatocyte nuclear DNA content and binuclearity in 62 patients with chronic hepatitis B or C. The percentage of 4n and 8n hepatocytes in the mononuclear hepatocyte population was compared with the percentage of 2 × 4n and 2 × 8n hepatocytes in the binuclear hepatocyte population. RESULTS： The percentages of 4n and 8n hepatocytes in mononuclear hepatocytes and 2 ×4n and 2 × 8n hepatocytes in binuclear hepatocytes were similar, regardless of the activity or fibrosis grade of chronic hepatitis and regardless of the infecting virus. CONCLUSION： The distribution of nuclear DNA content within mononuclear and binuclear hepatocyte populations was conserved during the course of chronic viral hepatitis.

关键词： Chronic viral hepatitis Hepatocyte binuclearity Hepatocyte ploidy Nuclear DNA content

Endoscopic papillectomy of minor papillar adenoma associated with pancreas divisum

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2009年第9期15卷 1138-1140页

作者： Akira Kanamori takashi kumada Seiki Kiriyama Yasuhiro Sone Makoto Tanikawa Yasuhiro Hisanaga Hidenori Toyoda Hiroki Kawashima Akihiro Itoh Yoshiki Hirooka Hidemi Goto Department of Gastroenterology Ogaki Municipal HospitalOgaki 503-8502Japan Department of Gastroenterology Nagoya University Graduate School ofMedicineNagoya 466-8560Japan Department of Gastroenterology Nagoya University Graduate School of MedicineNagoya 466-8560Japan Department of Endoscopy Nagoya University HospitalNagoya 466-8560Japan

Tumors of the minor papilla of the duodenum are quite *** successfully and safely treated an 18-mm adenoma of the minor papilla associated with pancreas divisum using endoscopic papillectomy.A 64-year-old man was admitted to our hospital for treatment of an asymptomatic mass in the minor papilla detected by upper gastrointestinal *** analysis showed an 18-mm,whitish,sessile mass,located in the duodenum proximal to a normal-appearing major *** retrograde pancreatography did not reveal the pancreatic *** resonance cholangiopancreatography showed a lack of the ventral pancreatic *** suspected this case was associated with pancreatic divisum;therefore,we performed endoscopic papillectomy of the minor papilla ***,endoscopic pancreatic stent placement in the minor papilla was done to prevent drainage *** patient has been asymptomatic without recurrence of tumor or stenosis of the Santorini orifice upon endoscopic examination for the past 2 years.

关键词： Endscopic papitlectomy Minor papill aradenoma Pancreas divisum Endoscopic pancreatic stent Endoscopic retrograde pancreatography

Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第17期22卷 4403-4410页

作者： Tomohiro Maekawa Yoshihiro Kamada Yusuke Ebisutani Makiko Ueda Tomoki Hata Koichi Kawamoto Shinji Takamatsu Kayo Mizutani Mayuka Shimomura Tomoaki Sobajima Hironobu Fujii Kotarosumitomo Nakayama Kimihiro Nishino Makoto Yamada takashi kumada Toshifumi Ito Hidetoshi Eguchi Hiroaki Nagano Eiji Miyoshi Department of Molecular Biochemistry and Clinical Investigation Osaka University Graduate School of Medicine Suita Osaka 565-0871 Japan Department of Surgery Osaka University Graduate School of Medicine Suita Suita Osaka 565-0871 Japan aMs New Otani Clinic Osaka Osaka 540-8570 Japan Department of Gastroenterology Ogaki Municipal Hospital Ogaki Gifu 503-8502 Japan Department of Gastroenterology and Hepatology Japan Community Health Care Organization Osaka Hospital Osaka Osaka 540-8570 Japan Department of Surgery Yamaguchi University Graduate School of Medicine Ube Yamaguchi 755-8505 Japan

AIM: To determine the efficacy of Mac-2 binding protein (Mac-2bp) for diagnosis of chronic ***: Fifty-nine healthy volunteers (HV), 162 patients with chronic pancreatitis (CP), and 94 patients with pancreatic ductal adenocarcinoma (PDAC) were enrolled in this study. We measured serum Mac-2bp using our developed enzyme-linked immunosorbent assay kit. Additional biochemical variables were measured using an automated analyzer (including aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, triglyceride, C-reactive protein, and amylase levels) or chemiluminescent enzyme immunoassay (carbohydrate antigen 19-9 and carcinoembryonic antigen). The ability of Mac-2bp to predict CP diagnosis accurately was assessed using receiver operating characteristic (ROC) ***: Serum Mac-2bp levels were significantly increased in CP patients compared to HV (P < 0.0001) and PDAC patients (P < 0.0001). Area under the ROC curve values of Mac-2bp for the discrimination of CP from HV and PDAC were 0.727 and 0.784, respectively. Multivariate analyses demonstrated that serum Mac-2bp levels were independent determinants for CP diagnosis from HV and PDAC patients. Immunohistological staining showed that Mac-2bp was expressed faintly in the pancreas tissues of both CP and PDAC patients. Serum aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, and triglyceride levels were significantly higher in patients with CP or PDAC. Serum Mac-2bp levels were highly correlated with protein levels of alanine aminotransferase, γ-glutamyltransferase, and C-reactive protein, but not amylase, suggesting that the damaged liver produces ***: Measurement of serum Mac-2bp may be a novel and useful biomarker for CP diagnosis as well as liver fibrosis in the general population.

关键词： Pancreatic ductal adenocarcinoma Chronic pancreatitis Biomarker Steatopancreatitis Mac-2 binding protein (LGALS3BP)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Gastroenterology Report 2021年第2期9卷 133-138,I0002页

作者： Atsushi Hiraoka takashi kumada Toshifumi Tada Chikara Ogawa Joji Tani Shinya Fukunishi Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Kazuya Kariyama Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Kazuhito Kawata Hidenori Toyoda Hideko Ohama Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Korenobu Hayama Taeang Arai Michitaka Imai Yohei Koizumi Shinichiro Nakamura Kojiro Michitaka Yoichi Hiasa Masatoshi Kudo Gastroenterology Center Ehime Prefectural Central HospitalEhimeJapan Department of Gastroenterology and Hepatology Ogaki Municipal HospitalGifuJapan Department of Internal Medicine Himeji Red Cross HospitalHyogoJapan Department of Gastroenterology and Hepatology Takamatsu Red Cross HospitalTakamatsuJapan Department of Gastroenterology and Hepatology Kagawa universityKagawaJapan Department of Gastroenterology Osaka Medical CollegeOsakaJapan Division of Gastroenterology and Hepatology Department of Internal MedicineNippon Medical SchoolTokyoJapan Department of Gastroenterology and Metabology Ehime University Graduate School of MedicineEhimeJapan Center of Gastroenterology Teine Keijinkai HospitalSapporoJapan Department of Gastroenterology Saiseikai Niigata HospitalNiigataJapan Department of Hepatology Kagawa Prefectural Central HospitalTakamatsuJapan Department of Gastroenterology Okayama City HospitalOkayamaJapan Department of Gastroenterology Asahi General HospitalAsahiJapan Department of Gastroenterology Toyama University HospitalToyamaJapan Division of Gastroenterology and Hepatology Otakanomori HospitalKashiwaJapan Department of Gastroenterology Tokushima Prefectural Central HospitalTokushimaJapan Hepato-biliary Center Matsuyama Red Cross HospitalMatsuyamaJapan Department of Hepatology Hamamatsu University School of MedicineHamamatsuJapan Department of Gastroenterology Kindai UniversityOsakaJapan

Background:Lenvatinib is used for unresectable hepatocellular carcinoma(u-HCC)as first-line,as well as second-and third-line therapy in *** evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression ***:Of 385 patients with u-HCC and treated with lenvatinib at 16 different institutions in Japan between May 2018 and January 2020,28 who received ramucirumab as the next treatment were enrolled and therapeutic responses were evaluated in a retrospective ***:The median age of the 28 patients given ramucirumab was 70 years and the median albumin-bilirubin score *** the 28 patients,23 were male,21 were classified as Child-Pugh A and 7 as Child-Pugh B,and 25 were Barcelona Clinic Liver Cancer Stage *** was given as second-line therapy in 14,third-line in 9,and fourth-line in *** response was obtained in only 26 patients;the objective response rate was 3.8%(1/26)and the disease-control rate was 42.3%(11/26),with a median period to progression of 2.0 *** reasons for discontinuation of ramucirumab were progression of disease in 16 and Grade 3 adverse events(gastrointestinal bleeding,ascites)in ***:The anticipated therapeutic efficacy of ramucirumab for post-progression treatment following lenvatinib was not seen in our early experience.

关键词： hepatocellular carcinoma ramucirumab lenvatinib sorafenib

Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatoma Research 2019年第5期5卷 26-36页

作者： Shinichiro Nakamura Kazuhiro Nouso Hiroyuki Okada Hideki Onishi Shin-ichi Fujioka YasuyukiAraki Shouta Iwadou takashi kumada Hidenori Toyoda Kenta Motomura Kazuya Kariyama Haruhiko Kobashi Toshihiko Kaneyoshi Masaharu Ando Akio Moriya Hideaki Taniguchi YouichiMorimoto Hiroaki Hagihara Masatoshi Tanaka Okayama University Graduate School of Medicine Dentistry and Pharmaceutical SciencesOkayama 700-8558Japan Okayama Saiseikai General Hospital Okayama 700-8558Japan Hiroshima City Hiroshima Citizens Hospital Hiroshima 731-0293Japan Ogaki Municipal Hospital Gifu 503-8502Japan Iizuka Hospital Fukuoka 820-8505Japan Okayama City Hospital Okayama 700-8557Japan Okayama Red Cross General Hospital Okayama 700-8607Japan Fukuyama Medical Center Hiroshima 720-8520Japan Mitoyo General Hospital Kagawa 769-1695Japan Tottori Municipal Hospital Tottori 680-8501Japan Kurashiki Central Hospital Okayama 710-8602Japan Sumitomo Besshi Hospital Ehime 792-8543Japan Yokokura Hospital Fukuoka 839-0215Japan Japanese Red Cross Society Himeji Hospital Hyogo 670-8540Japan

Aim:The increased risk of hepatocellular carcinoma(HCC)recurrence in hepatitis C virus(HCV)-infected patients treated with direct-acting antivirals(DAAs)after curative treatment for HCC is *** purpose of this study was to examine the risk of HCC recurrence after DAA ***:We conducted a retrospective cohort study of 312 consecutive patients with HCV-related HCC who received DAA therapy in participating institutions between September 2014 and July *** patients received curative ;hepatectomy or radio-frequency *** calculated the annual incidence of HCC recurrence after DAA therapy and identified the risk factors for HCC recurrence using Cox regression ***:The median age was 74 years old,and a sustained virological response was achieved by 288 *** 3-year-overall survival rate was 95.4%in a median follow-up period of 855 *** recurred in 135 *** 1-,2-and 3-year recurrence rates were 18.3%,38.8%and 55.4%,respectively.A multivariate analysis revealed that the following factors were associated with HCC recurrence:multiple tumors at the first HCC treatment[hazard ratio(HR)=2.21;95%CI:1.41-3.49],a history of multiple treatments for HCC(HR=1.97;95%CI:1.28-3.02),andα-fetoprotein(AFP-L3)≥10%at the initiation of DAA therapy(HR=4.74;95%CI:2.10-10.7).Conclusion:Among patients treated with DAAs after the curative treatment of HCC,multiple tumors at the first HCC treatment,multiple prior HCC treatments and a high AFP-L3 level before DAA therapy were associated with recurrence,and the rate of recurrence was comparable to that before the DAA era.

关键词： Hepatocellular carcinoma hepatitis C virus direct-acting antiviral recurrence

Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2024年第2期44卷 287-293页

作者： Kouya Shiraishi Atsushi Takahashi Yukihide Momozawa Yataro Daigo Syuzo Kaneko Takahisa Kawaguchi Hideo Kunitoh Shingo Matsumoto Hidehito Horinouchi Akiteru Goto Takayuki Honda Kimihiro Shimizu Masahiro Torasawa Daisuke Takayanagi Motonobu Saito Akira Saito Yuichiro Ohe Shun-ichi Watanabe Koichi Goto Masahiro Tsuboi Katsuya Tsuchihara Sadaaki Takata Tomomi Aoi Atsushi Takano Masashi Kobayashi Yohei Miyagi Kazumi Tanaka Hiroyuki Suzuki Daichi Maeda Takumi Yamaura Maiko Matsuda Yoko Shimada Takaaki Mizuno Hiromi Sakamoto Teruhiko Yoshida Yasushi Goto Tatsuya Yoshida Taiki Yamaji Makoto Sonobe Shinichi Toyooka Kazue Yoneda Katsuhiro Masago Fumihiro Tanaka Megumi Hara Nobuo Fuse Satoshi S.Nishizuka Noriko Motoi Norie Sawada Yuichiro Nishida Kazuki kumada Kenji Takeuchi Kozo Tanno Yasushi Yatabe Kuniko Sunami Tomoyuki Hishida Yasunari Miyazaki Hidemi Ito Mitsuhiro Amemiya Hirohiko Totsuka Haruhiko Nakayama Tomoyuki Yokose Kazuyoshi Ishigaki Toshiteru Nagashima Yoichi Ohtaki Kazuhiro Imai Ken Takasawa Yoshihiro Minamiya Kazuma Kobayashi Kenichi Okubo Kenji Wakai Atsushi Shimizu Masayuki Yamamoto Motoki Iwasaki Koichi Matsuda Johji Inazawa Yuichi Shiraishi Hiroyoshi Nishikawa Yoshinori Murakami Michiaki Kubo Fumihiko Matsuda Yoichiro Kamatani Ryuji Hamamoto Keitaro Matsuo takashi Kohno Division of Genome Biology National Cancer Center Research InstituteTokyoJapan Department of Clinical Genomics National Cancer Center Research InstituteTokyoJapan Laboratory for Statistical Analysis Center for Integrative Medical SciencesRIKENYokohamaJapan Department of Genomic Medicine Research InstituteNational Cerebral and Cardiovascular CenterOsakaJapan Laboratory for Genotyping Development Center for Integrative Medical SciencesRIKENYokohamaJapan Center for Antibody and Vaccine Therapy Research HospitalInstitute of Medical ScienceThe University of TokyoTokyoJapan Department of Medical Oncology and Cancer Center and Center for Advanced Medicine against CancerShiga University of Medical ScienceOtsuJapan Division of Medical AI Research and Development National Cancer Center Research InstituteTokyoJapan Center for Genomic Medicine Graduate School of MedicineKyoto UniversityKyotoJapan Department of Medical Oncology Japanese Red Cross Medical CenterTokyoJapan Department of Thoracic Oncology National Cancer Center Hospital EastJapan Department of Thoracic Oncology National Cancer Center HospitalTokyoJapan Department of Cellular and Organ Pathology Graduate School of MedicineAkita UniversityAkitaJapan Department of Respiratory Medicine Tokyo Medical and Dental UniversityBunkyo-kuTokyoJapan Division of General Thoracic Surgery Department of SurgeryShinshu University School of MedicineMatsumotoNaganoJapan Department of General Surgical Science Division of General Thoracic SurgeryGunma University Graduate School of MedicineIntegrative Center of General SurgeryGunma University HospitalGunmaJapan Department of Gastrointestinal Tract Surgery Fukushima Medical University School of MedicineFukushimaJapan StaGen Co. LtdTokyoJapan Division of Thoracic Surgery National Cancer Center HospitalTokyoJapan Department of Thoracic Surgery National Cancer Center Hospital EastChibaJapan Division of Translational Informatics Exploratory Oncology Research and Clinical Trial Center(EPOC

Dear editor,Lung carcinoma is responsible for the highest fatal-ity rate among cancer-related deaths globally,with lung adenocarcinoma(LADC)emerging as the prevailing sub-type.

关键词： adenocarcinoma lung Lung